By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Takeda Global Research & Development Center, Inc. 

One Takeda Parkway

Deerfield  Illinois  60015  U.S.A.
Phone: 224-554-6500 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Takeda Global Research & Development Center, Inc. Progressing Well in Asia With New Drug Applications (NDA) 10/4/2012 10:15:58 AM
Takeda Global Research & Development Center, Inc. Launches Phase III Clinical Trial in Asia for "TAK-875", a Potential Diabetic Treatment 9/26/2012 9:34:40 AM
Furiex Pharmaceuticals, Inc. (FURX) Confirms Takeda Global Research & Development Center, Inc.'s Announcement on the Acceptance of the EMA Submissions for Two Fixed-Dose Alogliptin Combination Therapies for the Treatment of Type 2 Diabetes 6/19/2012 10:06:04 AM
Affymax, Inc. (AFFY) and Takeda Global Research & Development Center, Inc. Report Additional Analyses of Peginesatide Phase 3 Studies in Dialysis Patients at the American Society of Nephrology’s Kidney Week 2011 11/11/2011 8:04:11 AM
Takeda Global Research & Development Center, Inc. Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 11/1/2011 6:51:39 AM
Affymax, Inc. (AFFY) and Takeda Global Research & Development Center, Inc. Announce FDA Acceptance of New Drug Application for Peginesatide 7/27/2011 7:33:26 AM
Takeda Global Research & Development Center, Inc. New Head-to-Head Phase 3 Study Evaluated Systolic Blood Pressure Reduction of Investigational Compound Azilsartan Medoxomil Compared to Valsartan 6/21/2010 9:55:21 AM
Affymax, Inc. (AFFY) and Takeda Global Research & Development Center, Inc. Announce Phase 3 Trials Meet Primary Endpoints for Investigational Drug, Hematide(TM)/peginesatide, to Treat Anemia in Chronic Renal Failure With Some Differences Noted in Secondary Analyses 6/21/2010 9:04:47 AM
Affymax, Inc. (AFFY) and Takeda Global Research & Development Center, Inc. Report Phase 2 Analyses of Hematide(TM)/peginesatide in Hemodialysis Patients 4/15/2010 8:33:33 AM
Affymax, Inc. (AFFY) and Takeda Global Research & Development Center, Inc. to Present HematideTM/peginesatide Phase 2 Data at the National Kidney Foundation 2010 Spring Meeting 3/30/2010 8:38:28 AM
12
//-->